Ibrutinib has some activity in Richter’s syndrome

被引：0
|
作者：
S Giri
A Hahn
G Yaghmour
M G Martin
机构：
[1] The University of Tennessee Health Science Center,Department of Medicine
[2] The West Clinic,Department of Hematology/Oncology
来源：
Blood Cancer Journal | 2015年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：e277 / e277
相关论文
共 50 条
  • [1] Ibrutinib has some activity in Richter's syndrome
    Giri, S.
    Hahn, A.
    Yaghmour, G.
    Martin, M. G.
    BLOOD CANCER JOURNAL, 2015, 5 : e277 - e277
  • [2] The efficacy of ibrutinib in the treatment of Richter syndrome
    Tsang, Mazie
    Shanafelt, Tait D.
    Call, Timothy G.
    Ding, Wei
    Chanan-Khan, Asher
    Leis, Jose F.
    Nowakowski, Grzegorz S.
    Bowen, Deborah
    Conte, Michael
    Schwager, Susan M.
    Slager, Susan L.
    Kay, Neil E.
    Hanson, Curtis A.
    Parikh, Sameer A.
    BLOOD, 2015, 125 (10) : 1676 - 1678
  • [3] An experience with ibrutinib monotherapy for Richter?s syndrome isolated in the central nervous system
    Nato, Yuma
    Nagaharu, Keiki
    Inoue, Kanako
    Yabu, Kodai
    Sawaki, Akihiko
    Shiotani, Takuya
    Kageyama, Yuki
    Tanaka, Ken
    Ohshima, Koichi
    Miyashita, Hiroyuki
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2022, 62 (04) : 238 - 241
  • [4] Ibrutinib-induced rapid response in chemotherapy-refractory Richter's Syndrome
    Fischer-Maranta, A.
    Bastian, S.
    Mey, U.
    Cogliatti, S.
    Hohloch, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 157 - 157
  • [5] Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome
    Fischer, Angela
    Bastian, Sara
    Cogliatti, Sergio
    Mey, Ulrich
    Saub, Jenny
    Schanz, Urs
    Padberg, Barbara
    Hohloch, Karin
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (01) : 370 - 371
  • [6] Ibrutinib and rituximab induced rapid response in refractory Richter syndrome
    Lamar, Zanetta
    Kennedy, LeAnne
    Kennedy, Brooke
    Lynch, Mary
    Goad, Amanda
    Hurd, David
    McIver, Zachariah
    CLINICAL CASE REPORTS, 2015, 3 (07): : 615 - 617
  • [7] Differential transcriptomic profiling in ibrutinib-naive versus ibrutinib-resistant Richter syndrome
    Wang, Hanyin
    Tian, Shulan
    Zhao, Qing
    Blumenschein, Wendy
    Yearley, Jennifer H.
    Secreto, Charla R.
    Sinha, Sutapa
    Call, Timothy G.
    Wang, Yucai
    Parikh, Sameer A.
    Kenderian, Saad S.
    He, Rong
    Leis, Jose F.
    Shi, Min
    Van Dyke, Daniel L.
    Kay, Neil E.
    Slager, Susan L.
    Braggio, Esteban
    Yan, Huihuang
    Ding, Wei
    HEMATOLOGICAL ONCOLOGY, 2022, 40 (02) : 302 - 306
  • [8] BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome
    Visentin, Andrea
    Imbergamo, Silvia
    Scomazzon, Edoardo
    Pravato, Stefano
    Frezzato, Federica
    Bonaldi, Laura
    Pizzi, Marco
    Vio, Stefania
    Gregianin, Michele
    Burei, Marta
    Facco, Monica
    Semenzato, Gianpietro
    Piazza, Francesco
    Trentin, Livio
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (01) : 193 - 197
  • [9] Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib
    Kittai, Adam S.
    Huang, Ying
    Keiter, Ashleigh
    Beckwith, Kyle A.
    Goldstein, Daniel
    Bhat, Seema A.
    Bond, David A.
    Byrd, John C.
    Grever, Michael R.
    Rogers, Kerry A.
    Woyach, Jennifer A.
    BLOOD, 2021, 138 : 3731 - +
  • [10] IBRUTINIB EFFICACY AGAINST RELAPSING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN A PATIENT WITH PROLONGED REMISSION OF RICHTER'S SYNDROME
    Albi, E.
    Baldoni, S.
    Aureli, P.
    Dorillo, E.
    Del Papa, B.
    Ascani, S.
    Di Ianni, M.
    Falzetti, F.
    Sportoletti, P.
    HAEMATOLOGICA, 2017, 102 : 157 - 157
12345